In response to the crisis caused by COVID-19, Lilly is introducing the Lilly Insulin Value Program, allowing anyone with commercial insurance and those without insurance to fill their monthly prescription of Lilly insulin for $35. The program is effective today and covers most Lilly insulins. Details and more information can be found in the press release here: https://e.lilly/2wjEr7J.  

Please share information about this news with anyone who has trouble affording their insulin. Please consider sharing the following social media posts and images:

• https://twitter.com/LillyPad/status/1247476539337342976?s=20
• https://www.facebook.com/608609425821991/posts/3528671440482427​​​​​​
• https://www.linkedin.com/feed/update/urn:li:activity:6653242489887174656/

Lilly has introduced several solutions in recent years to help meet the individual financial circumstances of people living with diabetes that are still in effect during the COVID-19 crisis, including:

• The Lilly Diabetes Solution Center, through which representatives can direct people to the $35 savings card, as well as affordability options that may reduce their out-of-pocket costs further – such as free insulin for people with minimal income, or no income at all, that has been donated by Lilly to non-profit organizations.
• Three non-branded versions of our insulin options with list prices 50 percent lower than the branded versions.
• In January, the company announced plans to donate at least 200,000 KwikPens® to relief agencies over the next three years.